Agilon Health’s contract reset has restored profitability, but AGL remains a high-risk turnaround whose upside depends on sustaining medical-cost discipline through volatile utilization and CMS reimbursement changes.
Overview
Agilon Health operates a value-based-care enablement platform that helps independent community PCPs move from fee-for-service to full-risk care for Medicare seniors, combining payer contracting, actuarial tools, clinical workflows, and administrative support while leaving practices independent. Its principal revenue is PMPM capitation from Medicare Advantage and CMS risk arrangements; Medical Margin is revenue less medical-service expense, with ACO REACH shared savings as a secondary stream. The turnaround showed measurable progress in Q2 2026: revenue rose 7.2% year over year to $1.495 billion, GAAP net income was $18.0 million versus a $104.4 million loss, Medical Margin was $197 million versus negative $53 million, and adjusted EBITDA was $70 million versus negative $83 million. Results included approximately $22 million of favorable prior-period claims development. Management raised FY2026 revenue guidance to $5.775–$5.860 billion, Medical Margin to $465–$505 million, and adjusted EBITDA to $75–$95 million. **The key catalyst is the contract reset, which generated over $120 million of FY2026 value.** At $80.73 in late September 2026, shares traded at about 0.2x forward sales but 52.9x consensus FY2027 non-GAAP EPS of $1.82. **The investment remains a high-risk margin-stability turnaround**, with the report’s probability-weighted five-year value at $156.30 and substantial downside if claims costs reaccelerate.